hydroxyurea has been researched along with Pain in 107 studies
Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We compared daily pain, home analgesic use, and utilization among ambulatory adults in the randomized multicenter study of hydroxyurea in sickle cell anemia (MSH)." | 9.15 | The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. ( Ballas, SK; Bauserman, RL; McCarthy, WF; Smith, WR; Steinberg, MH; Swerdlow, PS; Waclawiw, MA, 2011) |
| "Hydroxyurea therapy can ameliorate the clinical course of sickle cell anemia in some adults with three or more painful crises per year." | 9.08 | Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. ( Barton, FB; Bonds, DR; Charache, S; Dover, GJ; Eckert, SV; McMahon, RP; Moore, RD; Terrin, ML, 1995) |
| "In patients with sickle cell disease, hydroxyurea decreases the number of pain crises experienced." | 8.12 | Impact of Hydroxyurea Starting Dose on Pain Outcomes in Patients with Sickle Cell Disease. ( Dayer, LE; King, D; Lakkad, M; Montgomery, C; Painter, JT; Wagner, R; Wilson, LA, 2022) |
| "In a cohort of children with sickle cell disease (SCD) and vaso-occlusive pain visits served through South Carolina's Medicaid system over a 6-year period (N 5 523), we compared the number of vaso-occlusive pain or acute chest syndrome (ACS)/pneumonia episodes, and outpatient or acute service costs in those treated or not treated with hydroxyurea (HU)." | 7.76 | Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. ( Jerrell, JM; Stallworth, JR; Tripathi, A, 2010) |
| " Sex, age, foetal haemoglobin (HbF), SCD type, painful vaso-occlusive crisis (PVO), blood parameters, flow-mediated vasodilation (FMV), and hydroxyurea use were all extracted." | 5.41 | Scoping Review of Predisposing Factors Associated with Sensorineural Hearing Loss in Sickle Cell Disease. ( Dagwa, I; Dahilo, E; Ibekwe, P; Ibekwe, T; Nnebe-Agumadu, U; Nnodu, O; Ramma, L; Rogers, C, 2023) |
| "Among children and adults with sickle cell anemia, the median number of pain crises over 48 weeks was lower among those who received oral therapy with l-glutamine, administered alone or with hydroxyurea, than among those who received placebo, with or without hydroxyurea." | 5.27 | A Phase 3 Trial of l-Glutamine in Sickle Cell Disease. ( Bellevue, R; Blake, OA; Gordeuk, VR; Guillaume, E; Hsu, LL; Kanter, J; Lanzkron, S; Lasky, JL; Miller, ST; Neumayr, LD; New, TN; Niihara, Y; Osunkwo, I; Panosyan, EH; Razon, RL; Sadanandan, S; Sarnaik, S; Sieger, L; Smith, WR; Stark, CW; Tran, LT; Vichinsky, EP; Viswanathan, K, 2018) |
| "There is evidence to suggest that hydroxyurea may be effective in decreasing the frequency of pain episodes and other acute complications in adults and children with sickle cell anaemia of HbSS or HbSβºthal genotypes and in preventing life-threatening neurological events in those with sickle cell anaemia at risk of primary stroke by maintaining transcranial Doppler velocities." | 5.22 | Hydroxyurea (hydroxycarbamide) for sickle cell disease. ( Nevitt, SJ; Rankine-Mullings, AE, 2022) |
| "We compared daily pain, home analgesic use, and utilization among ambulatory adults in the randomized multicenter study of hydroxyurea in sickle cell anemia (MSH)." | 5.15 | The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. ( Ballas, SK; Bauserman, RL; McCarthy, WF; Smith, WR; Steinberg, MH; Swerdlow, PS; Waclawiw, MA, 2011) |
| "The Multicenter Study of Hydroxyurea (HU) in Sickle Cell Anemia (MSH) previously showed that daily oral HU reduces painful sickle cell (SS) crises by 50% in patients with moderate to severe disease." | 5.12 | Hydroxyurea and sickle cell anemia: effect on quality of life. ( Ballas, SK; Barton, BA; Barton, FB; Bonds, DR; Eckman, JR; Koshy, M; Pegelow, CH; Swerdlow, P; Waclawiw, MA, 2006) |
| "Hydroxyurea therapy can ameliorate the clinical course of sickle cell anemia in some adults with three or more painful crises per year." | 5.08 | Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. ( Barton, FB; Bonds, DR; Charache, S; Dover, GJ; Eckert, SV; McMahon, RP; Moore, RD; Terrin, ML, 1995) |
| "Despite Food and Drug Administration (FDA) approval of hydroxyurea to reduce the frequency of vaso-occlusive episodes, sickle cell disease (SCD) has continued to be treated primarily with analgesics for pain relief." | 4.93 | Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. ( Telen, MJ, 2016) |
| " Vaso-occlusive painful crises are associated with recurrent and long-term use of analgesics/opioids and hydroxyurea (HU) by people living with SCD." | 4.93 | An Expert Review of Pharmacogenomics of Sickle Cell Disease Therapeutics: Not Yet Ready for Global Precision Medicine. ( Dandara, C; Mnika, K; Pule, GD; Wonkam, A, 2016) |
| " The introduction of penicillin prophylaxis, conjugated pneumococcal and Haemophilus influenzae type B vaccines have dramatically decreased the rate of life-threatening infections, while use of hydroxyurea in children has decreased pain and acute chest syndrome events." | 4.90 | The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease. ( DeBaun, MR; Kassim, AA, 2014) |
| "In patients with sickle cell disease, hydroxyurea decreases the number of pain crises experienced." | 4.12 | Impact of Hydroxyurea Starting Dose on Pain Outcomes in Patients with Sickle Cell Disease. ( Dayer, LE; King, D; Lakkad, M; Montgomery, C; Painter, JT; Wagner, R; Wilson, LA, 2022) |
| "In a cohort of children with sickle cell disease (SCD) and vaso-occlusive pain visits served through South Carolina's Medicaid system over a 6-year period (N 5 523), we compared the number of vaso-occlusive pain or acute chest syndrome (ACS)/pneumonia episodes, and outpatient or acute service costs in those treated or not treated with hydroxyurea (HU)." | 3.76 | Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. ( Jerrell, JM; Stallworth, JR; Tripathi, A, 2010) |
| "Children with sickle cell disease presenting to an emergency department with a pain crisis unresponsive to codeine were genotyped." | 3.74 | The effect of CYP2D6 polymorphisms on the response to pain treatment for pediatric sickle cell pain crisis. ( Brousseau, DC; Divakaran, K; Drendel, AL; McCarver, DG; Panepinto, JA, 2007) |
| " An attempt was made in 10 patients to reduce marrow hyperplasia by using hydroxyurea." | 3.70 | Bone pain in thalassaemia: assessment of DEXA and MRI findings. ( Angastiniotis, M; Aristidou, K; Eracleous, E; Kanakas, A; Pavlides, N; Posporis, T; Yerakaris, M, 1998) |
| "The only approved treatments for painful crises in many countries are hydroxyurea plus potent analgesics." | 3.11 | Cost-effectiveness analysis of adding omega-3 or vitamin D supplementation to standard therapy in treating painful crises of pediatric sickle cell disease patients. ( Abdelhalima, SM; Alshaeri, HK; Elberry, AA; Gamaleldin, MM; Hussein, RRS; Meabed, MH; Mohammad, BA; Murphy, JE, 2022) |
| "Hydroxyurea treatment was feasible and safe in children with sickle cell anemia living in sub-Saharan Africa." | 2.90 | Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa. ( Aygun, B; Lane, A; Latham, TS; McGann, PT; Olupot-Olupot, P; Santos, B; Stuber, SE; Tomlinson, G; Tshilolo, L; Ware, RE; Williams, TN, 2019) |
| "Clinical complications of sickle cell anemia begin in infancy." | 2.77 | Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. ( Brown, RC; Casella, JF; Howard, TH; Iyer, RV; Lebensburger, JD; Lu, M; Miller, ST; Rogers, ZR; Sarnaik, S; Wang, WC, 2012) |
| "Sixty sickle cell anemia children (5-18 years) with more than three episodes of vasoocclusive crises or blood transfusions per year were randomized to receive HU (n = 30) or placebo (n = 30) therapy." | 2.77 | Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. ( Bhatnagar, M; Desai, S; Jain, DL; Lodha, A; Sarathi, V, 2012) |
| "Hydroxyurea was associated with statistically significantly lower rates of initial and recurrent episodes of pain, dactylitis, acute chest syndrome, and hospitalization; even infants who were asymptomatic at enrollment had less dactylitis as well as fewer hospitalizations and transfusions if treated with hydroxyurea." | 2.77 | Impact of hydroxyurea on clinical events in the BABY HUG trial. ( Alvarez, O; Files, BA; Iyer, R; Kalpatthi, R; Lebensburger, J; Luo, Z; Miller, ST; Seaman, P; Thompson, B; Thornburg, CD; Wang, WC; Ware, RE, 2012) |
| "Patients with sickle cell anemia were treated with daily doses of hydroxyurea, to assess pharmacokinetics, toxicity, and increase in fetal hemoglobin (Hb) production in response to the drug." | 2.67 | Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. ( Ballas, SK; Charache, S; Dover, GJ; Eckert, S; Koshy, M; Milner, PF; Moore, RD; Orringer, EP; Phillips, G; Platt, OS, 1992) |
| "Hydroxyurea, indicated for managing sickle cell anemia (SCA), and L-glutamine, indicated for treating sickle cell disease (SCD), were the only pharmacotherapeutic options in this patient population before the approval of crizanlizumab by the U." | 2.66 | Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease. ( Gordeuk, VR; Han, J; Saraf, SL, 2020) |
| "New drugs and novel treatment approaches such as gene therapy are currently being tested." | 2.66 | [Sickle cell disease]. ( Dickerhoff, R; Distelmaier, L; Dührsen, U, 2020) |
| "Hydroxyurea has demonstrated efficacy in adults with sickle cell disease." | 2.44 | Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease. ( Bass, EB; Beach, MC; Haywood, C; Lanzkron, S; Park, H; Segal, JB; Strouse, JJ; Wilson, R; Witkop, C, 2008) |
| "Venous thrombosis is more frequent in PV than in ET; superficial or deep venous thromboses are seen." | 2.41 | [What vascular events suggest a myeloproliferative disorder?]. ( Caulier-Leleu, MT; Hachulla, E; Pasturel-Michon, U; Rose, C; Trillot, N, 2000) |
| "Sickle cell disease affects more than 30 million people worldwide, including 0." | 1.62 | Clinical Features and Outcome of Sickle Cell Disease in a Tertiary Center in Northern Lebanon: A Retrospective Cohort Study in a Local, Hospital-Associated Registry. ( Al Alam, C; El Ojaimi, C; Hamad, T; Inati, A; Kanakamedala, H; Pilipovic, V; Sabah, R, 2021) |
| " On long-term use (2-15 years) of 1500-2000 mg a day, there is a 9% risk of developing ulcers." | 1.56 | [An 84-year-old man with an ulcer on his ankle]. ( Houwing, RH; Sanders-Koers, R; van Berkum-Zandkamp, N, 2020) |
| "Pain is relatively infrequent in SCD infants and young children and commonly managed at home." | 1.40 | Pain characteristics and age-related pain trajectories in infants and young children with sickle cell disease. ( Aertker, L; Brodecki, D; Coleman, C; Dampier, C; Ely, B; Hyslop, T; Kesler, K; Leiby, B; Sendecki, JA; Stuart, M, 2014) |
| "Sickle cell disease is the most common inherited disease in the U." | 1.35 | The clinical care of adult patients with sickle cell disease. ( Howard, J; Olujohungbe, A, 2008) |
| "Pain is commonly associated with inflammation." | 1.33 | Differential effect of zileuton, a 5-lipoxygenase inhibitor, against nociceptive paradigms in mice and rats. ( Kulkarni, SK; Patil, CS; Singh, VP, 2005) |
| " More frequent analgesic dosing was reported on days with more intense pain." | 1.31 | Home management of pain in sickle cell disease: a daily diary study in children and adolescents. ( Brodecki, D; Dampier, C; Ely, E; O'Neal, P, 2002) |
| "Hydroxyurea (HU) has been shown to increase HbF production and therefore has the potential to prevent these crises in adult patients." | 1.30 | [Sickle cell anemia in children: value of hydroxyurea in severe forms]. ( Chantraine, JM; Dresse, MF; Hoyoux, C; Oury, AP, 1997) |
| "Hydroxyurea can increase fetal hemoglobin (HbF) and improve the clinical course of sickle cell disease (SCD) patients." | 1.29 | A cautionary note regarding hydroxyurea in sickle cell disease. ( Lubin, BH; Vichinsky, EP, 1994) |
| "We conclude that serotonin produces hyperalgesia by a direct action on the primary afferent neuron via the 5-HT1A subset of serotonin receptors." | 1.28 | Serotonin is a directly-acting hyperalgesic agent in the rat. ( Levine, JD; Taiwo, YO, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.87) | 18.7374 |
| 1990's | 14 (13.08) | 18.2507 |
| 2000's | 23 (21.50) | 29.6817 |
| 2010's | 45 (42.06) | 24.3611 |
| 2020's | 23 (21.50) | 2.80 |
| Authors | Studies |
|---|---|
| Allard, P | 1 |
| Alhaj, N | 1 |
| Lobitz, S | 1 |
| Cario, H | 1 |
| Jarisch, A | 1 |
| Grosse, R | 1 |
| Oevermann, L | 1 |
| Hakimeh, D | 1 |
| Tagliaferri, L | 1 |
| Kohne, E | 1 |
| Kopp-Schneider, A | 1 |
| Kulozik, AE | 1 |
| Kunz, JB | 1 |
| Hassan, Z | 1 |
| Iqbal, A | 1 |
| Zahoor, S | 1 |
| Ali, I | 1 |
| Iqbal, MM | 1 |
| Bibi, R | 1 |
| Dela-Pena, JC | 1 |
| King, MA | 1 |
| Brown, J | 1 |
| Nachar, VR | 1 |
| Jiao, B | 1 |
| Basu, A | 1 |
| Ramsey, S | 1 |
| Roth, J | 1 |
| Bender, MA | 1 |
| Quach, D | 1 |
| Devine, B | 1 |
| Kavanagh, PL | 1 |
| Fasipe, TA | 1 |
| Wun, T | 1 |
| Conran, N | 1 |
| de Alvarenga Maximo, C | 1 |
| Oliveira, T | 1 |
| Fertrin, KY | 1 |
| Lobo, C | 1 |
| Costa, FF | 1 |
| Yang, M | 1 |
| Elmuti, L | 1 |
| Badawy, SM | 3 |
| Abdelhalim, SM | 1 |
| Murphy, JE | 2 |
| Meabed, MH | 2 |
| Elberry, AA | 2 |
| Gamaleldin, MM | 2 |
| Shaalan, MS | 1 |
| Hussein, RRS | 2 |
| Rankine-Mullings, AE | 1 |
| Nevitt, SJ | 1 |
| Abdelhalima, SM | 1 |
| Alshaeri, HK | 1 |
| Mohammad, BA | 1 |
| Dayer, LE | 1 |
| Wagner, R | 1 |
| King, D | 1 |
| Lakkad, M | 1 |
| Wilson, LA | 1 |
| Montgomery, C | 1 |
| Painter, JT | 1 |
| Ibekwe, T | 1 |
| Nnodu, O | 2 |
| Nnebe-Agumadu, U | 1 |
| Dagwa, I | 1 |
| Dahilo, E | 1 |
| Ibekwe, P | 1 |
| Rogers, C | 1 |
| Ramma, L | 1 |
| Jeon, WJ | 1 |
| Joung, B | 1 |
| Moon, JH | 1 |
| Hino, C | 1 |
| Park, D | 1 |
| Pham, B | 1 |
| Castillo, DR | 1 |
| Chong, E | 1 |
| Kaur, S | 1 |
| Grismore, C | 1 |
| Cao, H | 1 |
| Hankins, JS | 1 |
| Brambilla, D | 1 |
| Potter, MB | 1 |
| Kutlar, A | 4 |
| Gibson, R | 1 |
| King, AA | 1 |
| Baumann, AA | 1 |
| Melvin, C | 1 |
| Gordeuk, VR | 5 |
| Hsu, LL | 2 |
| Nwosu, C | 1 |
| Porter, JS | 2 |
| Alberts, NM | 1 |
| Simon, J | 1 |
| Glassberg, JA | 1 |
| Lottenberg, R | 1 |
| DiMartino, L | 1 |
| Jacobs, S | 1 |
| Fernandez, ME | 1 |
| Bosworth, HB | 1 |
| Klesges, LM | 1 |
| Shah, N | 1 |
| Lim, SH | 1 |
| Dutta, D | 1 |
| Moore, J | 1 |
| Steinberg, MH | 4 |
| Han, J | 2 |
| Saraf, SL | 2 |
| van Berkum-Zandkamp, N | 1 |
| Houwing, RH | 1 |
| Sanders-Koers, R | 1 |
| Collins, AB | 1 |
| McTate-Acosta, EA | 1 |
| Williams, SE | 1 |
| Distelmaier, L | 1 |
| Dührsen, U | 1 |
| Dickerhoff, R | 1 |
| Pittman, DD | 1 |
| Hines, PC | 1 |
| Beidler, D | 1 |
| Rybin, D | 1 |
| Frelinger, AL | 1 |
| Michelson, AD | 1 |
| Liu, K | 1 |
| Gao, X | 1 |
| White, J | 1 |
| Zaidi, AU | 1 |
| Charnigo, RJ | 1 |
| Callaghan, MU | 1 |
| Kang, HA | 1 |
| Barner, JC | 1 |
| Issa, F | 1 |
| Dang, BN | 1 |
| Buck, WC | 1 |
| Chicumbe, S | 1 |
| Nicolau, N | 1 |
| Virate, C | 1 |
| Cassamo, N | 1 |
| Dias, A | 1 |
| Amodo, F | 1 |
| Inati, A | 1 |
| Al Alam, C | 1 |
| El Ojaimi, C | 1 |
| Hamad, T | 1 |
| Kanakamedala, H | 1 |
| Pilipovic, V | 1 |
| Sabah, R | 1 |
| García-Morin, M | 1 |
| López-Sangüos, C | 1 |
| Vázquez, P | 1 |
| Alvárez, T | 1 |
| Marañón, R | 1 |
| Huerta, J | 1 |
| Cela, E | 1 |
| Ingerski, LM | 1 |
| Arnold, TL | 1 |
| Banks, G | 1 |
| Wang, WC | 7 |
| Niihara, Y | 1 |
| Miller, ST | 5 |
| Kanter, J | 3 |
| Lanzkron, S | 2 |
| Smith, WR | 7 |
| Viswanathan, K | 1 |
| Sarnaik, S | 2 |
| Osunkwo, I | 2 |
| Guillaume, E | 1 |
| Sadanandan, S | 1 |
| Sieger, L | 1 |
| Lasky, JL | 1 |
| Panosyan, EH | 1 |
| Blake, OA | 1 |
| New, TN | 1 |
| Bellevue, R | 1 |
| Tran, LT | 1 |
| Razon, RL | 1 |
| Stark, CW | 1 |
| Neumayr, LD | 1 |
| Vichinsky, EP | 2 |
| Liles, DK | 1 |
| Alvarez, OA | 2 |
| Cançado, RD | 1 |
| Friedrisch, JR | 1 |
| Knight-Madden, JM | 1 |
| Bruederle, A | 1 |
| Shi, M | 1 |
| Zhu, Z | 1 |
| Ataga, KI | 2 |
| Gowhari, M | 1 |
| Jain, S | 1 |
| Molokie, RE | 1 |
| Cronin, RM | 1 |
| Dorner, TL | 1 |
| Utrankar, A | 1 |
| Allen, W | 1 |
| Rodeghier, M | 1 |
| Kassim, AA | 2 |
| Jackson, GP | 1 |
| DeBaun, MR | 2 |
| Tshilolo, L | 1 |
| Tomlinson, G | 1 |
| Williams, TN | 2 |
| Santos, B | 1 |
| Olupot-Olupot, P | 1 |
| Lane, A | 1 |
| Aygun, B | 1 |
| Stuber, SE | 1 |
| Latham, TS | 1 |
| McGann, PT | 1 |
| Ware, RE | 3 |
| Patel, S | 1 |
| Purohit, P | 1 |
| Jit, BP | 1 |
| Meher, S | 1 |
| Singh, A | 1 |
| Yan, K | 1 |
| Brandow, AM | 2 |
| Panepinto, JA | 3 |
| Ip, H | 1 |
| Kesse-Adu, R | 1 |
| Howard, J | 2 |
| Hart, N | 1 |
| Mulaku, M | 1 |
| Opiyo, N | 1 |
| Karumbi, J | 1 |
| Kitonyi, G | 1 |
| Thoithi, G | 1 |
| English, M | 1 |
| Patidar, OP | 1 |
| Patidar, R | 1 |
| Patidar, RP | 1 |
| Apanah, S | 1 |
| Rizzolo, D | 1 |
| Dampier, C | 4 |
| Ely, B | 1 |
| Brodecki, D | 2 |
| Coleman, C | 1 |
| Aertker, L | 1 |
| Sendecki, JA | 1 |
| Leiby, B | 1 |
| Kesler, K | 1 |
| Hyslop, T | 1 |
| Stuart, M | 1 |
| Oberoi, S | 1 |
| Das, R | 1 |
| Trehan, A | 1 |
| Ahluwalia, J | 1 |
| Bansal, D | 1 |
| Malhotra, P | 1 |
| Marwaha, RK | 1 |
| Nwenyi, E | 1 |
| Leafman, J | 1 |
| Mathieson, K | 1 |
| Ezeobah, N | 1 |
| Makani, J | 1 |
| Ofori-Acquah, SF | 1 |
| Wonkam, A | 2 |
| Ohene-Frempong, K | 1 |
| Rzodkiewicz, P | 1 |
| Gasinska, E | 1 |
| Maslinski, S | 1 |
| Bujalska-Zadrozny, M | 1 |
| Smith, TP | 1 |
| Schlenz, AM | 1 |
| Schatz, JC | 1 |
| Maitra, R | 1 |
| Sweitzer, SM | 1 |
| Stettler, N | 1 |
| McKiernan, CM | 1 |
| Melin, CQ | 1 |
| Adejoro, OO | 1 |
| Walczak, NB | 1 |
| Darbari, DS | 2 |
| Hampson, JP | 1 |
| Ichesco, E | 1 |
| Kadom, N | 1 |
| Vezina, G | 1 |
| Evangelou, I | 1 |
| Clauw, DJ | 1 |
| Taylor Vi, JG | 1 |
| Harris, RE | 1 |
| Geyer, H | 1 |
| Scherber, R | 1 |
| Kosiorek, H | 1 |
| Dueck, AC | 1 |
| Kiladjian, JJ | 1 |
| Xiao, Z | 1 |
| Slot, S | 1 |
| Zweegman, S | 1 |
| Sackmann, F | 1 |
| Fuentes, AK | 1 |
| Hernández-Maraver, D | 1 |
| Döhner, K | 1 |
| Harrison, CN | 1 |
| Radia, D | 1 |
| Muxi, P | 1 |
| Besses, C | 1 |
| Cervantes, F | 3 |
| Johansson, PL | 1 |
| Andreasson, B | 1 |
| Rambaldi, A | 1 |
| Barbui, T | 1 |
| Bonatz, K | 1 |
| Reiter, A | 1 |
| Boyer, F | 1 |
| Etienne, G | 1 |
| Ianotto, JC | 1 |
| Ranta, D | 1 |
| Roy, L | 1 |
| Cahn, JY | 1 |
| Maldonado, N | 1 |
| Barosi, G | 1 |
| Ferrari, ML | 1 |
| Gale, RP | 1 |
| Birgegard, G | 1 |
| Xu, Z | 1 |
| Zhang, Y | 1 |
| Sun, X | 1 |
| Xu, J | 1 |
| Zhang, P | 1 |
| te Boekhorst, PA | 1 |
| Commandeur, S | 1 |
| Schouten, H | 1 |
| Pahl, HL | 1 |
| Griesshammer, M | 1 |
| Stegelmann, F | 1 |
| Lehmann, T | 1 |
| Senyak, Z | 1 |
| Vannucchi, AM | 1 |
| Passamonti, F | 1 |
| Samuelsson, J | 1 |
| Mesa, RA | 1 |
| Telen, MJ | 1 |
| Mnika, K | 1 |
| Pule, GD | 1 |
| Dandara, C | 1 |
| van Tuijn, CF | 1 |
| Sins, JW | 1 |
| Fijnvandraat, K | 1 |
| Biemond, BJ | 1 |
| Liles, D | 1 |
| Cancado, R | 1 |
| Friedrisch, J | 1 |
| Guthrie, TH | 1 |
| Knight-Madden, J | 1 |
| Gualandro, S | 1 |
| Colella, MP | 1 |
| Rollins, SA | 1 |
| Stocker, JW | 1 |
| Rother, RP | 1 |
| Olujohungbe, A | 1 |
| Cortes-Burgos, LA | 1 |
| Zweifel, BS | 1 |
| Settle, SL | 1 |
| Pufahl, RA | 1 |
| Anderson, GD | 1 |
| Hardy, MM | 1 |
| Weir, DE | 1 |
| Hu, G | 1 |
| Happa, FA | 1 |
| Stewart, Z | 1 |
| Muthian, S | 1 |
| Graneto, MJ | 1 |
| Masferrer, JL | 1 |
| Bauserman, RL | 4 |
| Ballas, SK | 8 |
| McCarthy, WF | 4 |
| Swerdlow, PS | 2 |
| Waclawiw, MA | 6 |
| Barton, BA | 2 |
| Martínez-Trillos, A | 1 |
| Gaya, A | 1 |
| Maffioli, M | 1 |
| Arellano-Rodrigo, E | 2 |
| Calvo, X | 1 |
| Díaz-Beyá, M | 1 |
| Castro, OL | 2 |
| Stallworth, JR | 1 |
| Jerrell, JM | 1 |
| Tripathi, A | 1 |
| Jirovec, DL | 1 |
| Rees, DC | 1 |
| Gladwin, MT | 1 |
| Iyer, RV | 2 |
| Casella, JF | 2 |
| Minniti, CP | 1 |
| Rana, S | 1 |
| Thornburg, CD | 2 |
| Rogers, ZR | 3 |
| Kalpatthi, RV | 1 |
| Barredo, JC | 1 |
| Brown, RC | 2 |
| Sarnaik, SA | 1 |
| Howard, TH | 2 |
| Wynn, LW | 2 |
| Armstrong, FD | 1 |
| Files, BA | 2 |
| Goldsmith, JC | 1 |
| Huang, X | 1 |
| Thompson, BW | 1 |
| Lebensburger, JD | 2 |
| Lu, M | 1 |
| Kim, HY | 1 |
| Weiner, D | 1 |
| Wager, CG | 1 |
| Gallagher, D | 1 |
| Styles, L | 1 |
| Dampier, CD | 1 |
| Jain, DL | 1 |
| Sarathi, V | 1 |
| Desai, S | 1 |
| Bhatnagar, M | 1 |
| Lodha, A | 1 |
| Luo, Z | 1 |
| Kalpatthi, R | 1 |
| Iyer, R | 1 |
| Seaman, P | 1 |
| Lebensburger, J | 1 |
| Alvarez, O | 1 |
| Thompson, B | 1 |
| Kesen, MR | 1 |
| Goldberg, MF | 1 |
| Lutty, GA | 1 |
| Hoppe, C | 1 |
| Hagar, W | 1 |
| Malik, P | 1 |
| Yates, AM | 1 |
| Dedeken, L | 1 |
| Smeltzer, MP | 1 |
| Robitaille, N | 1 |
| Ely, E | 1 |
| O'Neal, P | 1 |
| Singh, VP | 2 |
| Patil, CS | 2 |
| Kulkarni, SK | 2 |
| Schnog, JB | 1 |
| Duits, AJ | 1 |
| Muskiet, FA | 1 |
| ten Cate, H | 1 |
| Rojer, RA | 1 |
| Brandjes, DP | 1 |
| Dorman, K | 1 |
| Quinn, CT | 1 |
| Shull, EP | 1 |
| Ahmad, N | 1 |
| Lee, NJ | 1 |
| Buchanan, GR | 1 |
| Barton, FB | 2 |
| Swerdlow, P | 1 |
| Eckman, JR | 1 |
| Pegelow, CH | 1 |
| Koshy, M | 2 |
| Bonds, DR | 2 |
| Meremikwu, M | 1 |
| Adjaoud, D | 1 |
| Couillard, S | 1 |
| Benkerrou, M | 1 |
| Girot, R | 1 |
| Brousse, V | 1 |
| Ferster, A | 1 |
| Bader-Meunier, B | 1 |
| Brousseau, DC | 1 |
| McCarver, DG | 1 |
| Drendel, AL | 1 |
| Divakaran, K | 1 |
| Tubman, VN | 1 |
| Bennett, CM | 1 |
| Luo, HY | 1 |
| Chui, DH | 1 |
| Heeney, MM | 1 |
| Solomon, LR | 1 |
| Brawley, OW | 1 |
| Cornelius, LJ | 1 |
| Edwards, LR | 1 |
| Gamble, VN | 1 |
| Green, BL | 1 |
| Inturrisi, C | 1 |
| James, AH | 1 |
| Laraque, D | 1 |
| Mendez, M | 1 |
| Montoya, CJ | 1 |
| Pollock, BH | 1 |
| Robinson, L | 1 |
| Scholnik, AP | 1 |
| Schori, M | 1 |
| Strouse, JJ | 1 |
| Wilson, R | 1 |
| Beach, MC | 1 |
| Haywood, C | 1 |
| Park, H | 1 |
| Witkop, C | 1 |
| Bass, EB | 1 |
| Segal, JB | 1 |
| Lubin, BH | 1 |
| Silver, RT | 1 |
| Charache, S | 3 |
| Terrin, ML | 1 |
| Moore, RD | 2 |
| Dover, GJ | 3 |
| Eckert, SV | 1 |
| McMahon, RP | 1 |
| Davies, SC | 1 |
| Bevan, DH | 1 |
| Jayabose, S | 1 |
| Tugal, O | 1 |
| Sandoval, C | 1 |
| Patel, P | 1 |
| Puder, D | 1 |
| Lin, T | 1 |
| Visintainer, P | 1 |
| Oury, AP | 1 |
| Hoyoux, C | 1 |
| Dresse, MF | 1 |
| Chantraine, JM | 1 |
| Udden, MM | 1 |
| Lo, MN | 1 |
| Sears, DA | 1 |
| Angastiniotis, M | 1 |
| Pavlides, N | 1 |
| Aristidou, K | 1 |
| Kanakas, A | 1 |
| Yerakaris, M | 1 |
| Eracleous, E | 1 |
| Posporis, T | 1 |
| Morris, K | 1 |
| Yale, SH | 1 |
| Nagib, N | 1 |
| Guthrie, T | 1 |
| Day, SW | 1 |
| Hachulla, E | 1 |
| Rose, C | 1 |
| Trillot, N | 1 |
| Caulier-Leleu, MT | 1 |
| Pasturel-Michon, U | 1 |
| Hernández-Boluda, JC | 1 |
| Carreras, E | 1 |
| Marín, P | 1 |
| Rovira, M | 1 |
| Solé, F | 1 |
| Lloveras, E | 1 |
| Espinet, B | 1 |
| Ocejo, A | 1 |
| Montserrat, E | 1 |
| Eckert, S | 1 |
| Milner, PF | 1 |
| Orringer, EP | 1 |
| Phillips, G | 1 |
| Platt, OS | 1 |
| Taiwo, YO | 1 |
| Levine, JD | 1 |
| Sparks, MK | 1 |
| Moshell, AN | 1 |
| Nigra, TP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Register Sichelzellkrankheit Der GPOH[NCT03327428] | 1,000 participants (Anticipated) | Observational [Patient Registry] | 2016-12-15 | Recruiting | |||
| A PHASE III, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF L GLUTAMINE THERAPY FOR SICKLE CELL ANEMIA AND SICKLE ß0-THALASSEMIA[NCT01179217] | Phase 3 | 230 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| Single-center Pilot Study: Nano-rheological Biomarkers for Patients With Sickle Cell Disease (SCD) Versus Control Subjects (Other Constitutional Red Blood Cell Diseases and Healthy Subjects)[NCT05530239] | 40 participants (Anticipated) | Observational | 2022-10-31 | Not yet recruiting | |||
| A Phase 1b Sequential Open Label Dose-Ranging Study of Safety, Pharmacokinetics, and Preliminary Activity of Benserazide in Subjects With Beta Thalassemia Intermedia and Sickle Cell Disease[NCT04432623] | Phase 1/Phase 2 | 36 participants (Anticipated) | Interventional | 2020-10-05 | Recruiting | ||
| REALIZING EFFECTIVENESS ACROSS CONTINENTS WITH HYDROXYUREA (REACH): A PHASE I/II PILOT STUDY OF HYDROXYUREA FOR CHILDREN WITH SICKLE CELL ANEMIA[NCT01966731] | Phase 1/Phase 2 | 635 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| Nonpharmacological Approaches Used by Parents of Children With Sickle Cell Disease and the Effectiveness of Education Given to Nonpharmacological Approaches[NCT04121247] | 163 participants (Actual) | Interventional | 2015-09-01 | Completed | |||
| Comparison of Sub-dissociative Intranasal Ketamine Plus Standard Pain Therapy Versus Standard Pain Therapy in the Treatment of Pediatric Sickle Cell Disease Vasoocclusive Crises in Resource-limited Settings: a Multi-centered, Randomized, Controlled Trial[NCT02573714] | 160 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | |||
| Crizanlizumab for Treating COVID-19 Vasculopathy[NCT04435184] | Phase 2 | 54 participants (Actual) | Interventional | 2020-07-09 | Completed | ||
| A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises[NCT01895361] | Phase 2 | 198 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| Aerobic Physical Fitness and Health-related Quality of Life in Children With Sickle Cell Disease.[NCT05995743] | 72 participants (Actual) | Observational | 2021-11-01 | Completed | |||
| Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients[NCT02565082] | 64 participants (Actual) | Interventional | 2015-09-30 | Completed | |||
| Evaluation of Impact of Disease on Quality of Life, Education and Socio-professional Integration of Adults and Parents of Children Living With Sickle- Cell Disease in France[NCT04413539] | 1,088 participants (Actual) | Observational | 2020-06-02 | Completed | |||
| Treatment With Hydoxycarbamide and L-Carnitine in Adult Patients With Severe Forms of Sickle Cell Anemia: An Overview[NCT05081349] | Phase 4 | 91 participants (Actual) | Interventional | 2017-01-10 | Completed | ||
| Evaluation of Sickle Cell Liver Disease[NCT01950429] | 42 participants (Actual) | Observational | 2013-10-16 | Completed | |||
| Low Dose Aspirin for Preventing Intrauterine Growth Restriction and Preeclampsia in Sickle Cell Pregnancy (PIPSICKLE): a Randomized Controlled Trial[NCT05253781] | Phase 3 | 476 participants (Anticipated) | Interventional | 2020-07-01 | Recruiting | ||
| National Transfusion Treatment Survey in Patients With Sickle Cell Disease (SCD)[NCT03397017] | 200 participants (Actual) | Observational | 2016-07-01 | Completed | |||
| Primary Prevention of Strokes in Nigerian Children With Sickle Cell Disease Affiliated Titles: Sickle Cell Disease - Stroke Prevention in Nigeria (SPIN) Trial[NCT01801423] | 29 participants (Actual) | Interventional | 2013-04-24 | Completed | |||
| Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG)[NCT00006400] | Phase 3 | 193 participants (Actual) | Interventional | 2000-08-31 | Completed | ||
| Preventing Acute Chest Syndrome by Transfusion Feasibility Study( PROACTIVE Feasibility Study)[NCT00951808] | 237 participants (Actual) | Interventional | 2009-07-31 | Completed | |||
| Quantitative and Prognostic Evaluation of Dense Red Blood Cells in Sickle Cell Children: Single-center Study From the Creteil (France) Pediatric Cohort[NCT02887118] | 82 participants (Actual) | Observational | 2015-12-31 | Terminated (stopped due to The recruiting centre was no longer presenting new patients for inclusion) | |||
| PINPOINT: Gaming Technology to Engage Adolescent Sickle Cell Patients in Precision Pain Management[NCT03291613] | 13 participants (Actual) | Interventional | 2017-01-15 | Completed | |||
| Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition[NCT04754711] | 70 participants (Anticipated) | Interventional | 2021-09-23 | Recruiting | |||
| Single-center Prospective Evaluation of Sickle Cell Patient Care in the CHU Brugmann Emergency Department[NCT02386657] | 104 participants (Actual) | Observational | 2012-11-30 | Completed | |||
| Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease (SCD) and B-Thalassemia[NCT00061568] | Phase 1/Phase 2 | 150 participants (Anticipated) | Interventional | 2004-07-16 | Recruiting | ||
| Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)[NCT00000586] | Phase 3 | 0 participants | Interventional | 1992-01-31 | Completed | ||
| Sickle Cell Disease (SCD) Biochip': Towards a Simple and Reliable Way to Monitor Sickle Cell Disease[NCT02824471] | 100 participants (Anticipated) | Observational | 2014-10-31 | Recruiting | |||
| Effect of Adenosine 2A Receptor Agonist Regadenoson on Microvascular Blood Flow in Sickle Cell Anemia[NCT01566890] | 200 participants (Anticipated) | Interventional | 2012-07-31 | Active, not recruiting | |||
| Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis[NCT01932554] | Phase 2 | 0 participants (Actual) | Interventional | 2013-11-30 | Withdrawn (stopped due to Insufficient recruitment) | ||
| Evaluation of Potential Synergy of Combining Hydroxyurea With Nitric Oxide Donors on Fetal Hemoglobin Synthesis in Patients With Sickle Cell Anemia[NCT00056433] | Phase 1 | 39 participants (Actual) | Interventional | 2003-03-10 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The number of emergency room visits or medical facility visits that occur from Week 0 to Week 48, will be used to evaluate the efficacy of oral L-glutamine as a treatment for sickle cell anemia and beta-0 thalassemia. (NCT01179217)
Timeframe: 48 weeks
| Intervention | Number of ER visits (Median) |
|---|---|
| L-glutamine | 1 |
| 100% Maltodextrin | 1 |
The number of hospitalizations that occur from Week 0 to Week 48, will be used to evaluate the efficacy of oral L-glutamine as a treatment for sickle cell anemia and beta-0 thalassemia. (NCT01179217)
Timeframe: 48 weeks
| Intervention | Number of hospitalizations (Median) |
|---|---|
| L-glutamine | 2 |
| 100% Maltodextrin | 3 |
The number of occurrences of protocol-defined sickle cell crises that occur from Week 0 to Week 48 will be used to evaluate the efficacy of oral L-glutamine as a treatment for sickle cell anemia and beta-0 thalassemia. (NCT01179217)
Timeframe: 48 weeks
| Intervention | Number of crises (Median) |
|---|---|
| L-glutamine | 3 |
| 100% Maltodextrin | 4 |
To assess the effect of oral L-glutamine on Vital signs (temperature). Change from Baseline will be reported at Weeks 4, 24, and 48. (NCT01179217)
Timeframe: Baseline, Week 4, Week 24 and Week 48
| Intervention | degree C (Mean) | |||
|---|---|---|---|---|
| Temperature at Baseline | Change in Temperature at Week 4 | Change in Temperature at Week 24 | Change in Temperature at Week 48 | |
| 100% Maltodextrin | 36.83 | -0.02 | 0.03 | 0.05 |
| L-glutamine | 36.85 | -0.06 | -0.05 | -0.09 |
To assess the effect of oral L-glutamine on hematological parameters (hemoglobin), Change from Baseline will be reported at Weeks 4, 24 and 48. (NCT01179217)
Timeframe: Baseline, Week 4, 24 and 48
| Intervention | g/dL (Mean) | |||
|---|---|---|---|---|
| Hemoglobin at Baseline | Change in Hemoglobin at week 4 | Change in Hemoglobin at Week 24 | Change in Hemoglobin at Week 48 | |
| L-glutamine | 8.82 | 0.04 | -0.17 | -0.12 |
| Placebo | 8.71 | 0.23 | -0.12 | -0.12 |
To assess the effect of oral L-glutamine on hematological parameters (hematocrit), Change from Baseline will be reported at Weeks 4, 24 and 48. (NCT01179217)
Timeframe: Baseline, Week 4, 24 and 48
| Intervention | % of red blood cells (Mean) | |||
|---|---|---|---|---|
| Hematocrit at Baseline | Change in Hematocrit at Week 4 | Change in Hematocrit Week 24 | Change in Hematocrit at Week 48 | |
| 100% Maltodextrin | 27.53 | 0.75 | -0.15 | 0.11 |
| L-glutamine | 27.67 | 0.16 | -0.26 | 0.16 |
To assess the effect of oral L-glutamine on hematological parameters (reticulocyte count), Change from Baseline will be reported at Weeks 4, 24 and 48. (NCT01179217)
Timeframe: Baseline, Week 4, 24 and 48
| Intervention | 1000 cells/uL (Mean) | |||
|---|---|---|---|---|
| Reticulocyte (Abs) | Change in Reticulocyte (Abs) at Week 4 | Change in Reticulocyte (Abs) at Week 24 | Change in Reticulocyte (Abs) at Week 48 | |
| 100% Maltodextrin | 295.03 | -23.09 | -1.93 | 26.27 |
| L-glutamine | 283.62 | -9.28 | 7.94 | 50.89 |
To assess the effect of oral L-glutamine on Vital signs (pulse rate). Change from Baseline will be reported at Weeks 4, 24, and 48. (NCT01179217)
Timeframe: Baseline, Week 4, Week 24 and Week 48
| Intervention | bpm (Mean) | |||
|---|---|---|---|---|
| Pulse Rate (bpm) at Baseline | Change in Pulse Rate (bpm) at Week 4 | Change in Pulse Rate (bpm) at Week 24 | Change in Pulse Rate (bpm) at 48 | |
| 100% Maltodextrin | 88.5 | -0.4 | -1.5 | 0.2 |
| L-glutamine | 85.6 | -0.1 | 3.0 | 1.1 |
To assess the effect of oral L-glutamine on Vital signs (respiration). Change from Baseline will be reported at Weeks 4, 24, and 48. (NCT01179217)
Timeframe: Baseline, Week 4, Week 24 and Week 48
| Intervention | breaths/min (Mean) | |||
|---|---|---|---|---|
| Respiration at Baseline | Change in Respiration at Week 4 | Change in Respiration at Week 24 | Change in Respiration at Week 48 | |
| 100% Maltodextrin | 19.1 | -0.2 | -0.6 | -0.6 |
| L-glutamine | 18.9 | -0.2 | -0.7 | -0.7 |
To assess the effect of oral L-glutamine on Vital signs (systolic and diastolic blood pressure). Change from Baseline will be reported at Weeks 4, 24, and 48. (NCT01179217)
Timeframe: Baseline, Week 4, 24, and 48
| Intervention | mm Hg (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Systolic blood pressure at Baseline | Change Systolic blood pressure at Week 4 | Change in Systolic blood pressure at Week 24 | Change in Systolic blood pressure at Week 48 | Diastolic blood pressure at Baseline | Change in Diastolic blood pressure at Week 4 | Change in Diastolic blood pressure at Week 24 | Change in Diastolic blood pressure at Week 48 | |
| 100% Maltodextrin | 114.6 | -0.2 | 0.5 | 2.6 | 66.2 | 0.3 | 0.6 | 2.0 |
| L-glutamine | 111.3 | 0.5 | 1.1 | 2.2 | 64.8 | -0.7 | -0.7 | 0.4 |
An expected toxicity rate of 20% and acceptable toxicity rate of 30% were used for statistical calculations. After 53 participants at each site complete 3 months of therapy, if ≤ 15 participants have hematologic toxicity there is no early evidence against safety. If ≥ 15 of the initial participants experience toxicity, this is early evidence against safety. Future participants will begin at a lower dose of hydroxyurea (10 ± 2.5 mg/kg), with another 53 participants recruited of the same safety analysis. Upon final analysis of 133 participants at the same starting dose, safety for fixed-dose hydroxyurea can be concluded. (NCT01966731)
Timeframe: 3 months
| Intervention | percentage of participants (Number) |
|---|---|
| Hydroxyurea | 5.1 |
Level of C-reactive protein (CRP) in mg/dL. (NCT04435184)
Timeframe: Day 14 after randomization
| Intervention | mg/dL (Median) |
|---|---|
| Crizanlizumab | 2.5 |
| Placebo Saline | 1.3 |
Level of C-reactive protein (CRP) in mg/dL. (NCT04435184)
Timeframe: Day 3 after randomization
| Intervention | mg/dL (Median) |
|---|---|
| Crizanlizumab | 4.4 |
| Placebo Saline | 4.5 |
Level of C-reactive protein (CRP) in mg/dL. (NCT04435184)
Timeframe: Day 7 after randomization
| Intervention | mg/dL (Median) |
|---|---|
| Crizanlizumab | 2.4 |
| Placebo Saline | 2.1 |
Level of D-dimer in mg/L. (NCT04435184)
Timeframe: Day 14 after randomization
| Intervention | mg/L (Median) |
|---|---|
| Crizanlizumab | 1.5 |
| Placebo Saline | 0.7 |
Level of D-dimer in mg/L. (NCT04435184)
Timeframe: Day 3 after randomization
| Intervention | mg/L (Median) |
|---|---|
| Crizanlizumab | 1.6 |
| Placebo Saline | 0.7 |
Level of D-dimer in mg/L. (NCT04435184)
Timeframe: Day 7 after randomization
| Intervention | mg/L (Median) |
|---|---|
| Crizanlizumab | 1.6 |
| Placebo Saline | 0.7 |
Safety of crizanlizumab will by assessed by adverse events, serious adverse events, and suspected unexpected serious adverse reactions. (NCT04435184)
Timeframe: Up to day 14 after randomization
| Intervention | total adverse events (Number) |
|---|---|
| Crizanlizumab | 7 |
| Placebo Saline | 6 |
Level of soluble P-selectin in ng/mL. (NCT04435184)
Timeframe: Day 14 after randomization
| Intervention | ng/mL (Mean) |
|---|---|
| Crizanlizumab | 12 |
| Placebo Saline | 48 |
Level of soluble P-selectin in ng/mL. (NCT04435184)
Timeframe: Day 3 after randomization or day of hospital discharge, whichever is earlier
| Intervention | ng/mL (Mean) |
|---|---|
| Crizanlizumab | 7 |
| Placebo Saline | 39 |
Level of soluble P-selectin in ng/mL. (NCT04435184)
Timeframe: Day 7 after randomization
| Intervention | ng/mL (Mean) |
|---|---|
| Crizanlizumab | 10 |
| Placebo Saline | 48 |
Time (days) to hospital discharge (NCT04435184)
Timeframe: Up to 30 days after randomization
| Intervention | days (Mean) |
|---|---|
| Crizanlizumab | 8.1 |
| Placebo Saline | 6.2 |
Level of von Willebrand Factor (VWF) antigen in IU/mL. (NCT04435184)
Timeframe: Day 3 after randomization
| Intervention | IU/mL (Median) |
|---|---|
| Crizanlizumab | 2.9 |
| Placebo Saline | 2.8 |
Level of VWF antigen in IU/mL. (NCT04435184)
Timeframe: Day 14 after randomization
| Intervention | IU/mL (Median) |
|---|---|
| Crizanlizumab | 2.7 |
| Placebo Saline | 4.6 |
Level of VWF antigen in IU/mL. (NCT04435184)
Timeframe: Day 7 after randomization
| Intervention | IU/mL (Median) |
|---|---|
| Crizanlizumab | 3.9 |
| Placebo Saline | 3.6 |
"Change in the clinical status over 14 days as measured by an ordinal scale that is the first assessment of the clinical status on a given study day. The scale is as follows:~0 = Uninfected; no viral RNA detected~= Ambulatory; asymptomatic; viral RNA detected~= Ambulatory; symptomatic; independent~= Ambulatory; symptomatic; assistance needed~= Hospitalized; no oxygen therapy~= Hospitalized; oxygen by mask or nasal prongs~= Hospitalized; oxygen by non-invasive ventilation (NIV) or high flow~= Hospitalized; intubation and mechanical ventilation, partial pressure of oxygen / fraction of inspired oxygen (pO2/FIO2) ≥ 150 or oxygen saturation / FIO2 (SpO2/FIO2) ≥ 200~= Hospitalized; intubation and mechanical ventilation, pO2/FIO2 < 150 or SpO2/FIO2 < 200 or vasopressors~= Hospitalized; intubation and mechanical ventilation, pO2/FIO2 < 150 or SpO2/FIO2 < 200 and vasopressors, dialysis, or extracorporeal membrane oxygenation (ECMO)~= Dead" (NCT04435184)
Timeframe: Days 3, 7 and 14 after randomization
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WHO Clinical Status: Day 372489589 | WHO Clinical Status: Day 372489590 | WHO Clinical Status: Day 772489590 | WHO Clinical Status: Day 772489589 | WHO Clinical Status: Day 1472489589 | WHO Clinical Status: Day 1472489590 | |||||||||||||||||||||||||||||||||||||||||||
| 10 | 4 | 5 | 6 | 7 | 8 | 9 | ||||||||||||||||||||||||||||||||||||||||||
| Placebo Saline | 2 | |||||||||||||||||||||||||||||||||||||||||||||||
| Crizanlizumab | 3 | |||||||||||||||||||||||||||||||||||||||||||||||
| Crizanlizumab | 13 | |||||||||||||||||||||||||||||||||||||||||||||||
| Placebo Saline | 7 | |||||||||||||||||||||||||||||||||||||||||||||||
| Placebo Saline | 4 | |||||||||||||||||||||||||||||||||||||||||||||||
| Crizanlizumab | 9 | |||||||||||||||||||||||||||||||||||||||||||||||
| Placebo Saline | 13 | |||||||||||||||||||||||||||||||||||||||||||||||
| Crizanlizumab | 5 | |||||||||||||||||||||||||||||||||||||||||||||||
| Crizanlizumab | 6 | |||||||||||||||||||||||||||||||||||||||||||||||
| Placebo Saline | 3 | |||||||||||||||||||||||||||||||||||||||||||||||
| Crizanlizumab | 1 | |||||||||||||||||||||||||||||||||||||||||||||||
| Crizanlizumab | 0 | |||||||||||||||||||||||||||||||||||||||||||||||
| Crizanlizumab | 21 | |||||||||||||||||||||||||||||||||||||||||||||||
| Placebo Saline | 19 | |||||||||||||||||||||||||||||||||||||||||||||||
| Placebo Saline | 1 | |||||||||||||||||||||||||||||||||||||||||||||||
| Placebo Saline | 0 | |||||||||||||||||||||||||||||||||||||||||||||||
Acute Chest Syndrome (ACS) is defined on the basis of the finding of a new pulmonary infiltrate involving at least one complete lung segment that was consistent with alveolar consolidation, but excluding atelectasis (as indicated by chest X-ray). At least one of the following additional signs or symptoms needs to be present as well: a participant had to have reported chest pain, a temperature of more than 38.5oC, tachypnea, wheezing or cough. (NCT01895361)
Timeframe: One year
| Intervention | accute chest syndrome per year (Median) |
|---|---|
| High-dose SelG1 (Selg1 5.0 mg/kg) | 0.00 |
| Low-dose SelG1 (Selg1 2.5 mg/kg) | 0.00 |
| Placebo | 0.00 |
The annual rate of days hospitalized was calculated as the number of days hospitalized multiplied by 365 divided by the end date minus the date of randomization plus one where the end date is defined as the last dose date plus 14 days (for subjects never dosed, the end date equaled the end of study date, which was the last site contact for these patients). (NCT01895361)
Timeframe: One year
| Intervention | Days hospitalized per year (Median) |
|---|---|
| High-dose SelG1 (Selg1 5.0 mg/kg) | 4.00 |
| Low-dose SelG1 (Selg1 2.5 mg/kg) | 6.87 |
| Placebo | 6.87 |
An SCPC is defined as an acute episode of pain with no other medically determined cause than a vasoocclusive event that requires a medical facility visit and treatment with oral or parenteral narcotics, or parenteral non-steroidal anti-inflammatory drugs. The annual rate of SCPC is defined as the total number of pain crises for a patient occurring from the date of randomization to the end date multiplied by 365 divided by the number of days during that same time period. End date is defined as the last dose date plus 14 days. For participants never dosed, the end date was the end of study date. This calculation accounts for early dropouts or lost to follow-up by extrapolating the SCPC rate of every participant to one year. (NCT01895361)
Timeframe: One year
| Intervention | SCPC per year (Median) |
|---|---|
| High-dose SelG1 (Selg1 5.0 mg/kg) | 1.63 |
| Low-dose SelG1 (Selg1 2.5 mg/kg) | 2.01 |
| Placebo | 2.98 |
An SCPC is defined as an acute episode of pain with no other medically determined cause than a vasoocclusive event that requires a medical facility visit and treatment with oral or parenteral narcotics, or parenteral non-steroidal anti-inflammatory drugs. The annual rate of SCPC is defined as the total number of pain crises for a patient occurring from the date of randomization to the end date multiplied by 365 divided by the number of days during that same time period. End date is defined as the last dose date plus 14 days. For participants never dosed, the end date was the end of study date. This calculation accounts for early dropouts or lost to follow-up by extrapolating the SCPC rate of every participant to one year. (NCT01895361)
Timeframe: One year
| Intervention | SCPC per year (Median) |
|---|---|
| High-dose SelG1 (Selg1 5.0 mg/kg) | 1.63 |
| Low-dose SelG1 (Selg1 2.5 mg/kg) | 2.01 |
| Placebo | 2.98 |
Uncomplicated SCPC is defined as an acute episode of pain with no known cause for pain other than a vasoocclusive event; requiring a visit to a medical facility; and requiring treatment with a parenteral or oral narcotic (including opiates), or parenteral NSAIDs; but is NOT classified as an acute chest syndrome, hepatic sequestration, splenic sequestration or priapism. (NCT01895361)
Timeframe: Up to one year
| Intervention | Uncomplicated SCPC per year (Median) |
|---|---|
| High-dose SelG1 (Selg1 5.0 mg/kg) | 1.08 |
| Low-dose SelG1 (Selg1 2.5 mg/kg) | 2.00 |
| Placebo | 2.91 |
Time to first SCPC is defined as months from randomization to first SCPC. A participant without SCPC before withdrawal or completion of the study is considered censored at the time of the end date. End date is defined as the last dose plus 14 days. For participants never dosed, the end date is the end of study date. (NCT01895361)
Timeframe: Up to one year
| Intervention | months (Median) |
|---|---|
| High-dose SelG1 (Selg1 5.0 mg/kg) | 4.07 |
| Low-dose SelG1 (Selg1 2.5 mg/kg) | 2.20 |
| Placebo | 1.38 |
Time to second SCPC is defined as months from randomization to second SCPC. A patient with less than two SCPC before withdrawal or completion of the study is considered censored at the time of the end date. End date is defined as the last dose plus 14 days. For patients never dosed, the end date is the end of study date. (NCT01895361)
Timeframe: Up to one year
| Intervention | months (Median) |
|---|---|
| High-dose SelG1 (Selg1 5.0 mg/kg) | 10.32 |
| Low-dose SelG1 (Selg1 2.5 mg/kg) | 9.20 |
| Placebo | 5.09 |
The BPI instrument was completed by the patients at pre-specified study visits prior to & during the Treatment & Follow-Up Evaluation Phases. Patients completed the brief pain inventory long-form, 1-week recall at the indicated pre-specified study visits. The BPI is a standardized self-reported questionnaire developed to provide information on the intensity of pain (the sensory dimension) as well as the degree to which pain interferes with function (the reactive dimension). The BPI also asks questions about pain relief, pain quality, & the patient's perception of the cause of pain. Since pain can be quite variable over a day, the BPI asks patients to rate their pain at the time of responding to the questionnaire (pain now), & also at its worst, least, & average over the previous week. The scorings for pain & interference have a range from 0 (no pain/no interference) to 10 (worst pain/complete interference). The BPI scoring manual was used to calculate scores for each domain. (NCT01895361)
Timeframe: Baseline, Day 15, Week 14, Week 26, Week 38, Week 52, and Week 58, up to 58 weeks
| Intervention | score on a scale (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pain Severity: Baseline (BL) (n=48,49,55) | Pain Severity: CFB to Day 15 (n=38,42,47) | Pain Severity: CFB to Week (Wk) 14 (n=32,33,33) | Pain Severity: CFB to Week 26 (n=27,31,32) | Pain Severity: CFB to Week 38 (n=25,29,29) | Pain Severity: CFB to Week 52 (n=18,23,22) | Pain Severity: CFB to Wk 58 follow up (n=27,33,30) | Pain Interference: BL (n=48,49,55) | Pain Interence: CFB to Day 15 (n=38,42,47) | Pain Interence: CFB to Wk 14 (n=32,33,33) | Pain Interference: CFB to Wk 26 (n=27,32,32) | Pain Interference: CFB to Wk 38 (n=25,29,29) | Pain Interference: CFB to Wk 52 (n=18,23,22) | Pain Interference: CFB to Wk 58 f/up (n=27,33,30) | |
| High-dose SelG1 (Selg1 5.0 mg/kg) | 4.363 | -0.123 | -0.146 | -0.377 | -0.267 | -0.634 | -0.145 | 4.643 | -0.674 | -0.213 | -0.583 | -0.866 | -1.014 | -0.476 |
| Low-dose SelG1 (Selg1 2.5 mg/kg) | 4.531 | 0.073 | -0.068 | -0.290 | 0.026 | 0.130 | 0.091 | 4.656 | -0.099 | -0.534 | -0.728 | -0.119 | -0.174 | -0.386 |
| Placebo | 4.129 | 0.355 | -0.152 | -0.563 | 0.333 | -0.310 | -0.444 | 4.995 | -0.816 | -0.039 | -0.821 | -0.221 | -0.819 | -0.802 |
DTPA GFR was originally a co-primary efficacy outcome for the study. Later in May 29, 2009, this measurement was discontinued because of statistical futility (an extremely small chance that the difference between treatment groups would be statistically significant for this outcome) and the small risk posed by the radiation exposure involved with performing the DTPA GFR test. Subjects who had missing data at baseline or 2 years measurement were excluded from the analysis (29 subjects from the hydroxurea, and 31 subjects from the placebo group excluded). (NCT00006400)
Timeframe: Before initiation of treatment and at 2 years
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Hydroxyurea | 22.56 |
| Placebo | 20.74 |
GFR was calculated using new Schwartz formula: 39.1× [height (cm)/serum creatinine (mg/dL)]0.516 × [1.8/cystatin C]0.294 × [30/blood urea nitrogen]0.169 × [1.099]if male × [height(m)/1.4]0.188. Children with missing baseline or 2 years GFR were excluded from the analysis. (NCT00006400)
Timeframe: Before initiation of treatment and at 2 years
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Hydroxyurea | 10.57 |
| Placebo | 14.33 |
Schwartz formula used to calculate GFR is: 0.55× height (cm)/serum creatinine (mg/dL). Where height is in cm and serum creatinine is in mg/dL. Children with missing baseline or 2 years GFR were excluded from the analysis. (NCT00006400)
Timeframe: Before initiation of treatment and at 2 years
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Hydroxyurea | 28.65 |
| Placebo | 33.36 |
First occurence of positive infiltrate on chest x-ray (NCT00951808)
Timeframe: Chest x-rays (CXR) were ordered for trial eligibility, as a result of clinical indications, or at discharge or 72 hours if no prior CXR.
| Intervention | participants (Number) | |
|---|---|---|
| Yes | No | |
| Adults | 11 | 85 |
| Children | 11 | 96 |
| Overall | 22 | 181 |
"Ten likert-type questions assessing user-friendliness of technology. Each question has five answer options that range from Strongly Agree to Strongly Disagree. Scores range from 0-100. A score of 68 or above is considered above average. All scores averaged." (NCT03291613)
Timeframe: After 1-hour usability session
| Intervention | units on a scale (Mean) |
|---|---|
| Pinpoint App | 86.67 |
24 reviews available for hydroxyurea and Pain
| Article | Year |
|---|---|
Incorporation of novel therapies for the management of sickle cell disease: A pharmacist's perspective.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Pain; Pharmacists | 2022 |
Health State Utilities for Sickle Cell Disease: A Catalog Prepared From a Systematic Review.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Child; Comorbidity; Cost-Benefit | 2022 |
Sickle Cell Disease: A Review.
Topics: Adult; Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; Antisickling Agents; Benzaldehydes; C | 2022 |
Health-Related Quality of Life and Adherence to Hydroxyurea and Other Disease-Modifying Therapies among Individuals with Sickle Cell Disease: A Systematic Review.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Medication Adherence; Pain; Quality of Life | 2022 |
Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Topics: Acute Chest Syndrome; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Hemoglobin, Sickle; Hu | 2022 |
Scoping Review of Predisposing Factors Associated with Sensorineural Hearing Loss in Sickle Cell Disease.
Topics: Anemia, Sickle Cell; Hearing Loss, Sensorineural; Humans; Hydroxyurea; Pain; Prospective Studies; Re | 2023 |
Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso-occlusive Pain Crises in Patients with Sickle Cell Disease.
Topics: Anemia, Sickle Cell; Animals; Antibodies, Monoclonal, Humanized; Glutamine; Humans; Hydroxyurea; P-S | 2020 |
[Sickle cell disease].
Topics: Anemia, Sickle Cell; Antineoplastic Agents; Erythrocytes; Erythrocytes, Abnormal; Humans; Hydroxyure | 2020 |
Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries.
Topics: Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Developing Countries; Evidence-Based Med | 2013 |
The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Chest Pain; Child; Hematopoietic Stem C | 2014 |
Sickle cell disease: new opportunities and challenges in Africa.
Topics: Africa; Anemia, Sickle Cell; Blood Transfusion; Humans; Hydroxyurea; Morbidity; Mortality; National | 2013 |
Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease.
Topics: Analgesics; Anemia, Sickle Cell; Animals; Antisickling Agents; Blood Coagulation; Cell Adhesion; Dru | 2016 |
An Expert Review of Pharmacogenomics of Sickle Cell Disease Therapeutics: Not Yet Ready for Global Precision Medicine.
Topics: Analgesics; Analgesics, Opioid; Anemia, Sickle Cell; Humans; Hydroxyurea; Pain; Pain Management; Pha | 2016 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Sickle-cell disease.
Topics: Acute Chest Syndrome; Africa; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Disease S | 2010 |
Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management.
Topics: Anemia, Sickle Cell; Blood Transfusion; Clinical Trials as Topic; Disease Management; Gastrointestin | 2012 |
Sickle cell disease; a general overview.
Topics: Anemia, Sickle Cell; Blood Transfusion; Constriction, Pathologic; Hemoglobin, Sickle; Hemolysis; Hum | 2004 |
Sickle cell disease; a general overview.
Topics: Anemia, Sickle Cell; Blood Transfusion; Constriction, Pathologic; Hemoglobin, Sickle; Hemolysis; Hum | 2004 |
Sickle cell disease; a general overview.
Topics: Anemia, Sickle Cell; Blood Transfusion; Constriction, Pathologic; Hemoglobin, Sickle; Hemolysis; Hum | 2004 |
Sickle cell disease; a general overview.
Topics: Anemia, Sickle Cell; Blood Transfusion; Constriction, Pathologic; Hemoglobin, Sickle; Hemolysis; Hum | 2004 |
Sickle cell crisis! Managing the pain.
Topics: Adaptation, Psychological; Adult; Analgesics; Anemia, Sickle Cell; Bone Marrow Transplantation; Flui | 2005 |
Sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Child, Preschool; Humans; Hydroxyurea; Pain; Penicillins | 2006 |
Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Fetal Hemoglobin; Hemoglobins; Humans; Hydroxyurea; | 2008 |
Complications of sickle cell anemia in adults: guidelines for effective management.
Topics: Adult; Analgesics, Opioid; Anemia, Sickle Cell; Brain Diseases; Chest Pain; Child; Child, Preschool; | 1999 |
Management of sickle cell disease.
Topics: Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Bone Marrow Transplantation; Fetal Hemo | 1999 |
Approach to the vaso-occlusive crisis in adults with sickle cell disease.
Topics: Acute Disease; Adult; Analgesics; Analgesics, Opioid; Anemia, Sickle Cell; Antisickling Agents; Arte | 2000 |
Sickle cell pain & hydroxyurea.
Topics: Adult; Algorithms; Anemia, Sickle Cell; Child; Decision Trees; Drug Monitoring; Fetal Hemoglobin; Hu | 2000 |
[What vascular events suggest a myeloproliferative disorder?].
Topics: Adult; Aged; Alkylating Agents; Arterial Occlusive Diseases; Cross-Sectional Studies; Erythromelalgi | 2000 |
17 trials available for hydroxyurea and Pain
| Article | Year |
|---|---|
Comparative effectiveness of adding Omega-3 or Vitamin D to standard therapy in preventing and treating episodes of painful crisis in pediatric sickle cell patients.
Topics: Anemia, Sickle Cell; Double-Blind Method; Fatty Acids, Omega-3; Humans; Hydroxyurea; Pain; Retrospec | 2022 |
Cost-effectiveness analysis of adding omega-3 or vitamin D supplementation to standard therapy in treating painful crises of pediatric sickle cell disease patients.
Topics: Anemia, Sickle Cell; Child; Cost-Benefit Analysis; Dietary Supplements; Fatty Acids, Omega-3; Humans | 2022 |
A multilevel mHealth intervention boosts adherence to hydroxyurea in individuals with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Female; Humans; Hydroxyurea; Male; Medication Adherence; Pain; Telemedic | 2023 |
Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by patient-reported outcomes, actigraphy, and biomarkers.
Topics: Actigraphy; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Female; Humans; | 2021 |
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2018 |
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2018 |
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2018 |
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2018 |
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2018 |
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2018 |
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2018 |
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2018 |
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2018 |
Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis.
Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Antibodies, Monoclonal; Antibodies, Monoclonal, Humani | 2019 |
Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
Topics: Africa South of the Sahara; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Dose- | 2019 |
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; D | 2017 |
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; D | 2017 |
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; D | 2017 |
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; D | 2017 |
Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antisickling Agents; Double-Blind Method | 2010 |
The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients.
Topics: Activities of Daily Living; Adolescent; Adult; Analgesics; Anemia, Sickle Cell; Chronic Disease; Fem | 2011 |
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Blood Cell Count; Child | 2011 |
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Blood Cell Count; Child | 2011 |
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Blood Cell Count; Child | 2011 |
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Blood Cell Count; Child | 2011 |
Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study.
Topics: Acute Disease; Anemia, Sickle Cell; Antisickling Agents; Double-Blind Method; Fever; Hemoglobins; Hu | 2012 |
Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Child; Female; Fetal Hemogl | 2012 |
Impact of hydroxyurea on clinical events in the BABY HUG trial.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Double-Blind Metho | 2012 |
Impact of hydroxyurea on clinical events in the BABY HUG trial.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Double-Blind Metho | 2012 |
Impact of hydroxyurea on clinical events in the BABY HUG trial.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Double-Blind Metho | 2012 |
Impact of hydroxyurea on clinical events in the BABY HUG trial.
Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Antisickling Agents; Child, Preschool; Double-Blind Metho | 2012 |
Hydroxyurea and sickle cell anemia: effect on quality of life.
Topics: Activities of Daily Living; Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Cell Count; Doubl | 2006 |
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adult; Anemia, Sickle Cell; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxyurea; Mal | 1995 |
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adult; Anemia, Sickle Cell; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxyurea; Mal | 1995 |
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adult; Anemia, Sickle Cell; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxyurea; Mal | 1995 |
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adult; Anemia, Sickle Cell; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxyurea; Mal | 1995 |
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adult; Anemia, Sickle Cell; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxyurea; Mal | 1995 |
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adult; Anemia, Sickle Cell; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxyurea; Mal | 1995 |
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adult; Anemia, Sickle Cell; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxyurea; Mal | 1995 |
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adult; Anemia, Sickle Cell; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxyurea; Mal | 1995 |
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adult; Anemia, Sickle Cell; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxyurea; Mal | 1995 |
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adult; Anemia, Sickle Cell; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxyurea; Mal | 1995 |
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adult; Anemia, Sickle Cell; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxyurea; Mal | 1995 |
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adult; Anemia, Sickle Cell; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxyurea; Mal | 1995 |
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adult; Anemia, Sickle Cell; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxyurea; Mal | 1995 |
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adult; Anemia, Sickle Cell; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxyurea; Mal | 1995 |
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adult; Anemia, Sickle Cell; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxyurea; Mal | 1995 |
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Topics: Adult; Anemia, Sickle Cell; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxyurea; Mal | 1995 |
Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia.
Topics: Adult; Alanine Transaminase; Anemia, Sickle Cell; Chromosome Aberrations; Chromosome Disorders; Dose | 1992 |
Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia.
Topics: Adult; Alanine Transaminase; Anemia, Sickle Cell; Chromosome Aberrations; Chromosome Disorders; Dose | 1992 |
Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia.
Topics: Adult; Alanine Transaminase; Anemia, Sickle Cell; Chromosome Aberrations; Chromosome Disorders; Dose | 1992 |
Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia.
Topics: Adult; Alanine Transaminase; Anemia, Sickle Cell; Chromosome Aberrations; Chromosome Disorders; Dose | 1992 |
66 other studies available for hydroxyurea and Pain
| Article | Year |
|---|---|
Genetic modifiers of fetal hemoglobin affect the course of sickle cell disease in patients treated with hydroxyurea.
Topics: Anemia, Sickle Cell; Child, Preschool; Fetal Hemoglobin; gamma-Globins; Humans; Hydroxyurea; Metallo | 2022 |
Hydroxyurea- a cost effective treatment in developing countries for Atypical Chronic Myeloid Leukemia (aCML): Case Report of Two Patients.
Topics: Aged; Cost-Benefit Analysis; Developing Countries; Humans; Hydroxyurea; Leukemia, Myeloid, Chronic, | 2022 |
Safe use of hydroxycarbamide in sickle cell disease patients hospitalized for painful vaso-occlusive episodes during the randomized, open-label HELPS study.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Pain | 2022 |
Impact of Hydroxyurea Starting Dose on Pain Outcomes in Patients with Sickle Cell Disease.
Topics: Analgesics, Opioid; Anemia, Sickle Cell; Humans; Hydroxyurea; Pain; Practice Patterns, Physicians' | 2022 |
An innovative intervention for the prevention of vaso-occlusive episodes in sickle cell disease.
Topics: Anemia, Sickle Cell; Hemoglobin, Sickle; Humans; Hydroxyurea; Pain; Pain Management | 2023 |
Rifaximin for sickle cell disease.
Topics: Adult; Analgesics, Opioid; Anemia, Sickle Cell; Anti-Bacterial Agents; beta-Thalassemia; Cellular Se | 2019 |
Treating sickle cell anemia: A new era dawns.
Topics: Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; Benzaldehydes; Child; Fetal Hemoglobin; Fore | 2020 |
[An 84-year-old man with an ulcer on his ankle].
Topics: Aged, 80 and over; Ankle; Antineoplastic Agents; Hematologic Neoplasms; Humans; Hydroxyurea; Long Te | 2020 |
The role of pain rehabilitation in an adolescent sickle cell disease population: a case series.
Topics: Adolescent; Analgesics; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Chronic Pain; F | 2020 |
The association between hydroxyurea adherence and opioid utilization among Texas Medicaid enrollees with sickle cell disease.
Topics: Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Presc | 2020 |
Quality of life assessments in a cohort of Mozambican children with sickle cell disease.
Topics: Adolescent; Analgesics, Opioid; Anemia, Sickle Cell; Caregivers; Child; Child, Preschool; Cohort Stu | 2020 |
Clinical Features and Outcome of Sickle Cell Disease in a Tertiary Center in Northern Lebanon: A Retrospective Cohort Study in a Local, Hospital-Associated Registry.
Topics: Anemia, Sickle Cell; Cohort Studies; Hospitals; Humans; Hydroxyurea; Lebanon; Pain; Registries; Retr | 2021 |
Lactate Dehydrogenase: A Marker of the Severity of Vaso-Occlusive Crisis in Children with Sickle Cell Disease Presenting at the Emergency Department.
Topics: Adolescent; Analgesics, Opioid; Anemia, Sickle Cell; Arterial Occlusive Diseases; Child; Child, Pres | 2016 |
Clinic Attendance of Youth With Sickle Cell Disease on Hydroxyurea Treatment.
Topics: Adolescent; Ambulatory Care; Anemia, Sickle Cell; Child; Child, Preschool; Family Characteristics; F | 2017 |
High inpatient dose of opioid at discharge compared to home dose predicts readmission risk in sickle cell disease.
Topics: Adult; Analgesia, Patient-Controlled; Analgesics, Opioid; Anemia, Sickle Cell; Antisickling Agents; | 2019 |
Increased Patient Activation Is Associated with Fewer Emergency Room Visits and Hospitalizations for Pain in Adults with Sickle Cell Disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusion; Cross-Sectional Stud | 2019 |
Pregnancy outcomes in women with sickle cell disease: a retrospective study from Eastern India.
Topics: Abortion, Induced; Abortion, Spontaneous; Anemia, Sickle Cell; Antisickling Agents; Blood Transfusio | 2019 |
Longitudinal Trend in Emergency Department Reliance for Pain Among Sickle Cell Disease Patients in Wisconsin.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Cohort Studies | 2019 |
Low flow nocturnal oxygen therapy does not suppress haemoglobin levels or increase painful crises in sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Erythropoiesis; Erythropoietin; Female; Hemoglobins | 2013 |
Postcoital generalised pruritus as a first symptom of polycythaemia vera.
Topics: Antineoplastic Agents; Blood Cell Count; Chronic Inducible Urticaria; Hematocrit; Humans; Hydroxyure | 2013 |
Sickle cell disease: taking a multidisciplinary approach.
Topics: Analgesics; Anemia, Sickle Cell; Antisickling Agents; Erythrocyte Transfusion; Hematopoietic Stem Ce | 2013 |
Pain characteristics and age-related pain trajectories in infants and young children with sickle cell disease.
Topics: Age Factors; Anemia, Sickle Cell; Child, Preschool; Female; Follow-Up Studies; Health Services; Hosp | 2014 |
HbSD-Punjab: clinical and hematological profile of a rare hemoglobinopathy.
Topics: Acute Chest Syndrome; Anemia; Antisickling Agents; Child; Child, Preschool; Chromatography, High Pre | 2014 |
Differences in quality of life between pediatric sickle cell patients who used hydroxyurea and those who did not.
Topics: Adolescent; Age Factors; Anemia, Sickle Cell; Antisickling Agents; Child; Cross-Sectional Studies; D | 2014 |
Antinociceptive properties of esculetin in non-inflammatory and inflammatory models of pain in rats.
Topics: Analgesia; Analgesics; Animals; Arachidonate 5-Lipoxygenase; Disease Models, Animal; Hydroxyurea; Hy | 2015 |
Modulation of pain in pediatric sickle cell disease: understanding the balance between endothelin mediated vasoconstriction and apelin mediated vasodilation.
Topics: Adolescent; Age Factors; Anemia, Sickle Cell; Antisickling Agents; Apelin; Biomarkers; Child; Child, | 2015 |
Proportion of adults with sickle cell anemia and pain crises receiving hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Databases, Factual; Female; Humans; Hydroxyurea; In | 2015 |
Frequency of Hospitalizations for Pain and Association With Altered Brain Network Connectivity in Sickle Cell Disease.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Brain; Brain Mapping; Child; Female; Fetal Hem | 2015 |
Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Fatigue; Female; Fever; Humans; Hydroxyurea; | 2016 |
Hydroxyurea and Pain History in Relation to Patient-Reported Outcomes Using PROMIS Measures and the Frequency of Assessments in Sickle Cell Disease Patients.
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Pain; Patient Reported Outcome Measur | 2017 |
Reply to comment on: Hydroxyurea and pain history in relation to patient-reported outcomes using PROMIS® measures and the frequency of assessments in sickle cell disease patients.
Topics: Anemia, Sickle Cell; Antisickling Agents; Humans; Hydroxyurea; Pain; Patient Reported Outcome Measur | 2017 |
Daily pain in adults with sickle cell disease-a different perspective.
Topics: Adult; Analgesics; Analgesics, Opioid; Anemia, Sickle Cell; Anti-Inflammatory Agents, Non-Steroidal; | 2017 |
The clinical care of adult patients with sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Female; Genetic Testing; Heart Diseases; Humans; Hy | 2008 |
CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain.
Topics: Administration, Oral; Animals; Arachidonate 5-Lipoxygenase; Blotting, Western; Cell Line; Disease Mo | 2009 |
Climatic and geographic temporal patterns of pain in the Multicenter Study of Hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Atmospheric Pressure; Climate; Cold Temperature; Fe | 2009 |
Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antisickling Agents; Bone and Bones; Female; Humans; Hydroxy | 2010 |
Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex, age, and geographical location.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Analgesics, Non-Narcotic; Anemia, Sickle Cell; Climat | 2010 |
Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease.
Topics: Acute Chest Syndrome; Adolescent; Anemia, Sickle Cell; Child; Child, Preschool; Cohort Studies; Cost | 2010 |
Hydroxyurea in children with sickle cell disease: practice patterns and barriers to utilization.
Topics: Anemia, Sickle Cell; Attitude of Health Personnel; Child; Contraception; Data Collection; Drug Monit | 2010 |
Pain in sickle cell disease: the future of acute treatment.
Topics: Acute Disease; Anemia, Sickle Cell; Biomarkers; Humans; Hydroxyurea; Pain; Vascular Diseases | 2011 |
Inpatient management of sickle cell pain: a 'snapshot' of current practice.
Topics: Acute Chest Syndrome; Adolescent; Adult; Aged; Analgesia, Patient-Controlled; Anemia, Sickle Cell; B | 2012 |
Hydroxyurea treatment of children with hemoglobin SC disease.
Topics: Acute Chest Syndrome; Adolescent; Antisickling Agents; Child; Child, Preschool; Female; Hemoglobin S | 2013 |
Pain at home in sickle cell disease: an underrecognized problem.
Topics: Absenteeism; Adolescent; Adult; Analgesia; Anemia, Sickle Cell; Biomarkers; Child; Home Nursing; Hum | 2002 |
Home management of pain in sickle cell disease: a daily diary study in children and adolescents.
Topics: Absenteeism; Adolescent; Adult; Analgesics, Non-Narcotic; Anemia, Sickle Cell; Biomarkers; Child; Ch | 2002 |
Effect of zileuton in radicular pain induced by herniated nucleus pulposus in rats.
Topics: Animals; Female; Hydroxyurea; Intervertebral Disc Displacement; Pain; Pain Measurement; Rats; Rats, | 2004 |
Differential effect of zileuton, a 5-lipoxygenase inhibitor, against nociceptive paradigms in mice and rats.
Topics: Acetates; Acetic Acid; Analgesics; Animals; Capillary Permeability; Carrageenan; Cyclopropanes; Dose | 2005 |
Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia.
Topics: Acute Disease; Anemia, Sickle Cell; Arterial Occlusive Diseases; beta-Thalassemia; Blood Transfusion | 2007 |
Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia.
Topics: Acute Disease; Anemia, Sickle Cell; Arterial Occlusive Diseases; beta-Thalassemia; Blood Transfusion | 2007 |
Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia.
Topics: Acute Disease; Anemia, Sickle Cell; Arterial Occlusive Diseases; beta-Thalassemia; Blood Transfusion | 2007 |
Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia.
Topics: Acute Disease; Anemia, Sickle Cell; Arterial Occlusive Diseases; beta-Thalassemia; Blood Transfusion | 2007 |
[Physiopathology and treatment of sickle cell anemia].
Topics: Analgesics; Anemia, Sickle Cell; Blood Transfusion; Bone Marrow Transplantation; Fluid Therapy; Foli | 2007 |
Steroid treatment in children with sickle-cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Arthritis; Autoimmune Diseases; Blood Transfusion; Child; Child, Pr | 2007 |
The effect of CYP2D6 polymorphisms on the response to pain treatment for pediatric sickle cell pain crisis.
Topics: Adolescent; Analgesics, Opioid; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; C | 2007 |
Sickle cell disease caused by Hb S/Québec-CHORI: treatment with hydroxyurea and response.
Topics: Abdominal Pain; Acute Disease; Anemia, Sickle Cell; Cholecystectomy; Cholecystitis; Exchange Transfu | 2007 |
Treatment and prevention of pain due to vaso-occlusive crises in adults with sickle cell disease: an educational void.
Topics: Acute Disease; Analgesics, Opioid; Anemia, Sickle Cell; Clinical Competence; Humans; Hydroxyurea; Op | 2008 |
National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Biomedical Research; Child; Delivery of | 2008 |
Pathophysiology and management of sickle cell pain crisis. Report of a Meeting of Physicians and Scientists, University of Texas Health Science Center at Houston, Texas.
Topics: Adult; Anemia, Sickle Cell; Cell Adhesion; Chronic Disease; Endothelium, Vascular; Erythrocytes; Ery | 1995 |
A cautionary note regarding hydroxyurea in sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Blood Transfusion; Cerebral Hemorrhage; Cerebrovascular Disorders; Femal | 1994 |
Hydroxyurea and sickle cell crisis.
Topics: Anemia, Sickle Cell; Humans; Hydroxyurea; Leukemia; Pain; Polycythemia Vera | 1995 |
Sickle cell pain crisis.
Topics: Anemia, Sickle Cell; Antisickling Agents; Erythropoietin; Female; Hemoglobins; Humans; Hydroxyurea; | 1996 |
Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Female; Fetal Hemoglobin; Follow-Up Stu | 1996 |
[Sickle cell anemia in children: value of hydroxyurea in severe forms].
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Drug Administration S | 1997 |
Successful hydroxyurea treatment of a patient with SD hemoglobinopathy.
Topics: Anemia, Sickle Cell; Female; Hemoglobin SC Disease; Hemoglobins, Abnormal; Humans; Hydroxyurea; Midd | 1999 |
Bone pain in thalassaemia: assessment of DEXA and MRI findings.
Topics: Absorptiometry, Photon; Adult; Aging; beta-Thalassemia; Blood Transfusion; Bone and Bones; Bone Dens | 1998 |
Addressing the crisis of care for sickle-cell disease.
Topics: Antisickling Agents; Attitude to Health; Critical Care; Humans; Hydroxyurea; Nitric Oxide; Pain; Sic | 1999 |
Collection of Philadelphia-negative stem cells using recombinant human granulocyte colony-stimulating factor in chronic myeloid leukemia patients treated with alpha-interferon.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Component | 2002 |
Serotonin is a directly-acting hyperalgesic agent in the rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Dose-Response Relationship, Drug; Hydroxyurea; Hype | 1992 |
The effect of increased fetal hemoglobin production on the frequency of vaso-occlusive crisis in sickle cell disease.
Topics: Anemia, Sickle Cell; Azacitidine; Centrifugation, Density Gradient; Erythrocytes; Fetal Hemoglobin; | 1987 |
Hydroxyurea and pain in psoriatic lesions during ultraviolet-B radiation.
Topics: Aged; Female; Humans; Hydroxyurea; Middle Aged; Pain; Photochemotherapy; Psoriasis | 1985 |